U.S. stock futures slip lower; Cook’s firing increases Fed independence worries
Investing.com -- Mirion Technologies Inc (NYSE:MIR), a provider of radiation detection and monitoring solutions, saw its shares tumble 8% despite reporting second-quarter results that exceeded analyst expectations, as investors appeared concerned about revised organic growth guidance.
The company reported adjusted earnings per share of $0.11 for the second quarter ended June 30, 2025, beating the analyst estimate of $0.10. Revenue rose 7.6% YoY to $222.9 million, surpassing the consensus estimate of $217.04 million. The company swung to a GAAP net income of $8.5 million, a 171% improvement from a GAAP net loss of $12.0 million in the same period last year.
Despite the positive quarterly results, Mirion’s stock dropped sharply as the company revised its organic revenue growth guidance to 5.0%-7.0% from the previous 5.5%-7.5%, citing reductions in Labs & Research and Dosimetry end-markets expectations, which more than offset increased growth in the Nuclear Power segment.
"Our second quarter results demonstrate continued progress towards key 2025 financial targets and positively position us to capture robust market dynamics," said Thomas Logan, Mirion’s Chairman and Chief Executive Officer. "Nuclear power and cancer care tailwinds remain vibrant and Mirion is better positioned than ever to capitalize on these favorable market trends."
The company raised its full-year 2025 guidance for total revenue growth to 7.0%-9.0% from 5.0%-7.0% previously, and increased its adjusted EBITDA forecast to $223-$233 million from $215-$230 million. Mirion also boosted its adjusted EPS guidance to $0.48-$0.52, compared to the analyst consensus of $0.49.
During the quarter, Mirion completed a $400 million convertible notes offering, refinanced its Term Loan B, and announced the acquisition of Certrec to expand its services and software offerings in the nuclear power market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.